Single: signature enabling glioma enrollment

The Defense Health Agency (DHA) awarded Translational Genomics Research Institute (TGen) a $192,000 project grant effective September 1, 2025, through August 31, 2027, under the Military Medical Research and Development program (CFDA 12.420). Titled "Single: Signature Enabling Glioma Enrollment," this award supports research activities focused on glioma investigation and patient enrollment strategies. As a non-profit research organization specializing in precision medicine and translational bioscience, TGen will deliver advanced scientific services including genomic analyses, molecular profiling, and computational analysis capabilities to advance the DHA's medical research objectives.

The award aligns with the Military Medical Research and Development program's broader mission to transform healthcare for service members and the American public through innovative biomedical research. TGen's established expertise in genomic sequencing, disease research, and multi-institutional collaboration positions the institute to contribute to the program's emphasis on precision medicine and translational research initiatives. The two-year performance period allows for comprehensive investigation and development of glioma-related research findings that may inform medical solutions and therapeutic strategies.